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Background: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a common cause of
morbidity and mortality. Traditional Chinese medicine (TCM) is used to treat AECOPD as adjunctive therapy. This
study aimed to evaluate the efficacy and safety of the TCM formula Xuan Bai Cheng Qi as an adjuvant therapy for
AECOPD patients with the syndrome type of phlegm-heat obstructing the lungs.
Methods: A multicenter, randomized, double-blind, placebo-controlled clinical trial was conducted. A total of 244
patients were divided into the intervention group (n = 122, treated with conventional medicine and Xuan Bai
Cheng Qi) and the control group (n = 122, treated with conventional medicine and placebo). Total symptom scores
(cough, phlegm, wheezing, chest congestion) before treatment and at 3, 5, 7, 10 days post-treatment were
recorded. Lung function, arterial blood gas, serum inflammatory cytokines, oxidation/anti-oxidation index were
observed before treatment and at the end of the 10-day treatment.
Results: A total of 242 patients completed the study. The full analysis set (FAS) population was 244 and the
per-protocol analysis set (PPS) population was 229. After the 10-day treatment, symptom scores of the Xuan Bai
Cheng Qi group were significantly lower over time compared with the control group (FAS: mean difference −1.84,
95% CI −2.66 to −1.03, P < .001; PPS: mean difference −1.87, 95% CI −2.71 to −1.03, P < .001). FEV1, FVC, and FEV1%
pred were significantly higher over time in the Xuan Bai Cheng Qi group compared with those in the control group
(day 10, FAS and PPS: P < .05). PaO2 and PaCO2 were significantly improved in the Xuan Bai Cheng Qi group (day
10, FAS and PPS: P < .05). Xuan Bai Cheng Qi was also found to ameliorate cytokine levels and oxidation/antioxidant
index compared with placebo. There were no differences in safety variables and adverse events between the two
groups.
Conclusions: Xuan Bai Cheng Qi formula appears to be a safe and beneficial treatment for AECOPD of
phlegm-heat obstructing the lungs syndrome type.
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Chronic obstructive pulmonary disease (COPD) is defined
by irreversible or partially reversible airway obstruction in
persons with chronic bronchitis or emphysema. Experts
predict that COPD will become the fourth leading cause
of death worldwide by 2030 [1].
Hastening of normal reduction in lung function that
occurs with age and repeated exacerbations are key fea-
tures of COPD. Acute exacerbation of chronic obstruct-
ive pulmonary disease (AECOPD) is a common cause of
morbidity and mortality in COPD patients [2]. These
exacerbations are associated with worsening respiratory
symptoms and lung function [3]. Median time post-
exacerbation to recovery of peak flow is 6 days and time
to recovery from symptoms is 7 days [4].
Many etiologic factors contribute to COPD exacerba-
tions such as continued smoking, respiratory tract infec-
tions, and exposure to particles from air pollution and
the work environment. Upper respiratory tract infections
are the most common triggering factor of COPD exacer-
bations. Thus, the management of exacerbations creates
an enormous burden on health care services [5].
Traditional Chinese medicine (TCM) is used exten-
sively in the treatment of AECOPD in Asia, particularly
in China. The effects of TCM, especially herbal medi-
cines, in improving respiratory symptoms and decreas-
ing the incidence of COPD exacerbations are well
known. One such herbal medicine is Xuan Bai Cheng
Qi formula. In Chinese medicine, the primary syndrome
type of AECOPD is phlegm-heat obstructing the lungs
[6]. The actions of Xuan Bai Cheng Qi formula are to
clear lung heat and dissipate phlegm, so for this reason
it is commonly prescribed for AECOPD [7]. The remedy
consists of four Chinese herbs: Gypsum fibrosum (gyp-
sum), Rheum officinale Baill (rhubarb root and rhizome),
Armeniacae amarum (apricot seed or kernel), and Tricho-
santhes kirilowii (trichosanthes peel) (Table 1). Xuan Bai
Cheng Qi is a classical prescription dating to the Qing
Dynasty (late 1700s) text Systematic Differentiation of
Warm Pathogen Diseases by Wu Jutong. Our previous
studies found that Xuan Bai Cheng Qi improves oxidant/
antioxidant imbalance, pulmonary inflammation in the rat
model of COPD [8,9]. Clinical studies have postulated that
Xuan Bai Cheng Qi is effective as a supplemental remedyTable 1 Medicinals in Xuan Bai Cheng Qi formula
Chinese name (pinyin) Latin name English commo
Sheng Shi Gao Gypsum fibrosum Gypsum
Sheng Dahuang Rheum officinale Baill Unprocessed rhu
Ku Xing Ren Armeniacae amarum Bitter apricot see
Gua Lou Pi Trichosanthes kirilowii Trichosanthes pe
aAmount of each medicinal if formula were prepared as a decoction.
bAmount of each medicinal used in preparing granule form of this formula.for treating AECOPD or respiratory failure [10,11]. How-
ever, due to the limited sample sizes and methodological
problems apparent in these studies the evidence for
the effectiveness of Xuan Bai Cheng Qi was not robust.
Therefore, we performed a multicenter, randomized,
double-blind, placebo-controlled clinical trial to evalu-
ate the efficacy and safety of Xuan Bai Cheng Qi in the
treatment of AECOPD of the syndrome type phlegm-
heat obstructing the lungs.
Methods
Ethics and trial registration
This study was approved by the research ethics commit-
tees at all participating centers and on file at Dongzhimen
Hospital affiliated to Beijing University of Chinese
Medicine (DZMSP20090302). This trial was registered




AECOPD diagnosis was based on criteria established by
the Global Initiative for Chronic Obstructive Lung Disease
(GOLD, 2007 version) [12], and by the Chinese Society of
Respiratory Diseases (2007 version) [13].
Diagnostic criteria for TCM syndrome of phlegm-heat
obstructing lung was based on State Administration of
Traditional Chinese Medicine guidelines [14] and criteria
outline by Wang and Lu [15]. Primary symptoms were:
cough and/or gasping for breath; yellow and viscous
sputum. Accompanying symptoms were: irritability and
restlessness; abdominal distension; thirst with desire for
cool drink; fever without chills; yellow urine; constipa-
tion with hard stool; red tongue with yellow or yellow
greasy coating; slippery and rapid pulse. Phlegm-heat
obstructing the lungs was diagnosed when any two pri-
mary symptoms along with any two accompanying symp-
toms were present.
Inclusion and exclusion criteria
Persons of either gender were included in the study if
they: met the diagnostic criteria of AECOPD; met TCM
diagnostic criteria for syndrome of phlegm-heat obstruct-
ing lung; had symptoms defined by GOLD as level 1 to 4;n name Daily decoction
dosea (g)
Dose per 1,000 g
granuleb (g)
30 435
barb root and rhizome 18 261
d 12 174
el 9 130
Liu et al. BMC Complementary and Alternative Medicine 2014, 14:239 Page 3 of 11
http://www.biomedcentral.com/1472-6882/14/239were aged between 18 to 85 years; were within 5 days
post-AECOPD; had not participated in other interven-
tional trials in the previous 1 month; and were willing to
participate in the study voluntarily and signed an informed
consent.
Persons were excluded from the study if they had any
of the following: airflow limitation due to bronchiectasis,
cystic fibrosis, lung cancer, or other respiratory disease;
co-morbidities such as acute heart failure, acute cerebral
hemorrhage, gastrointestinal bleeding, aplastic anemia, or
other severe or life-threatening diseases; unstable hyper-
tension, coronary heart disease, or diabetes; mental dis-
ease, severe neurologic deficits or other disorders that
impaired understanding or cooperation with the investiga-
tion; serious liver, kidney, or hematopoietic disease; recent
use of immunosuppressive agents; known allergy to herbs
or drugs used in the trial. Women planning to become or
were pregnant or breastfeeding were also excluded.Participant enrollment
Participants in the trial were inpatients diagnosed with
AECOPD of the syndrome phlegm-heat obstructing the
lungs. They were recruited and enrolled on a rolling basis
and observed from October 2009 through January 2013.
Eight teaching hospitals in China were a part of the trial:
Dongzhimen Hospital affiliated to Beijing University of
Chinese Medicine (40 cases; 16.4%); Dongfang Hospital
affiliated to Beijing University of Chinese Medicine (26
cases; 10.7%); Shanghai Shuguang Hospital affiliated to
Shanghai University of Chinese Medicine (45 cases; 18.4%);
University Hospital of Gansu Traditional Chinese
Medicine (10 cases; 4.1%); First Affiliated Hospital of
Anhui University of Chinese Medicine (23 cases; 9.4%);
Hebei Provincial Hospital of Chinese Medicine (38
cases; 15.6%); Henan Province Kaifeng City Hospital of
Traditional Chinese Medicine (18 cases; 7.4%);Table 2 Application of antibiotics at each stage of AECOPD
COPD stage of acute
exacerbation
Microorganisms
GOLD stages I and II Haemophilus influenzae, Streptococcus pneu
Moraxella catarrhalis
GOLD stages III and IV; no risk
factors for infection with
Pseudomonas aeruginosa
Haemophilus influenzae, Streptococcus pneu
Moraxella catarrhalis, Klebsiella pneumoniae
Escherichia coli, Enterobacteriacea
GOLD stages III and IV; risk
factors for infection with
Pseudomonas aeruginosa
All above microorganisms plus Pseudomon
aeruginosa
Abbreviations: AECOPD acute exacerbation of chronic obstructive pulmonary disease
Chronic Obstructive Lung Disease.Affiliated Hospital of Liaoning University of Traditional
Chinese Medicine (44 cases; 18.0%).
Treatments
Conventional therapy
All participants in the trial and control groups were given
conventional treatment based on GOLD [12] and the
Chinese Society of Respiratory Diseases [13]. Conventional
medicine regimen: oxygen therapy (1–3 L/min) by nasal
cannula or Venturi mask; open-label cefotaxime 2 g daily
(iv q 12 h) for 10 days or an alternate antibiotic if the pa-
tient was allergic to or intolerant of cefotaxime (Table 2);
inhaled long-acting β-agonist (either salmeterol or for-
moterol) and an inhaled long-acting anticholinergic
bronchodilator (tiotropium) after randomization; if the
patient was using an inhaled steroid or inhaled steroid/
long-acting β-agonist combination product at the time
of randomization, this medication was continued for
patients in both groups; if the patient’s baseline FEV1
was <50% of predicted, 30–40 mg prednisolone per day
for 7–10 days was administered. Supplemental salbuta-
mol, ambroxol, and aminophylline were given as needed
throughout the trial period.
Experimental and control treatments
Participants in the intervention group received Xuan
Bai Cheng Qi formula in granule form as an adjunct to
conventional therapy (Table 1). Participants in the con-
trol group received conventional therapy plus placebo
granules.
Manufacturing and administration of Xuan Bai Cheng Qi
and placebo granules
Both Xuan Bai Cheng Qi granules and the placebo gran-
ules were produced and packaged by Jiang Yin Tian
Jiang Pharmaceutical Co. Ltd. (Jiangsu, China) underAntibiotics
moniae, Penicillin, beta lactamase/enzyme inhibitor (amoxicillin/
clavulanic acid), macrolides (clarithromycin, roxithromycin,
azithromycin), first generation (cefazolin, cefradine) or




Beta-lactam/enzyme inhibitor (cefuroxime), second
generation cephalosporins, fluoroquinolones (levofloxacin,
moxifloxacin, gatifloxacin), third generation cephalosporins
(ceftriaxone, cefotaxime).
as Third generation cephalosporins (ceftazidime),
cefoperazone/sulbactam, piperacillin/tazobactam, imipenem,
meropenem, can also be combined with aminoglycosides,
fluoroquinolones (ciprofloxacin).
, COPD chronic obstructive pulmonary disease, GOLD Global Initiative for
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(Approval Number: 0905301–4).
Xuan Bai Cheng Qi granules were prepared by decoct-
ing the four herbs together, resulting in a concentrated
liquid and extraction and capture of the volatile oils.
The concentrated liquid was spray-dried on a starch base
powder to obtain the final product. Each package of gran-
ules was 4.5 g. Quality of the granules was tested for
consistency with industry standards.
The placebo granules were designed to taste, smell,
and resemble the Xuan Bai Cheng Qi granules.
Participants were given packages of Xuan Bai Cheng
Qi or placebo granules to prepare on their own over the
10-day trial period. Four packages were to be taken each
day by dissolving the granules in 300 mL boiled water
with 150 mL taken twice daily. To assess adherence, at
the completion of the trial on day 10, participants turned
in used and unused packages of granules to research
team nurses.
At the start of the trial, participants were instructed
not to receive other TCM therapy associated with the
treatment of AECOPD.
Outcome measures
A case report form (CRF) was designed by the research
steering committee. Spot checks were conducted through-
out the trial by seven independent reviewers from within
the steering committee to check completion of the CRF
and conformance to the protocol. Randomly selected
CRFs were reviewed during the trial to ensure quality.
Primary outcome measure was symptom scores, which
were assessed and recorded on day 1, 3, 5, 7, 10. Second-
ary outcome measures were lung function, arterial blood
gas analysis, pro-inflammatory biomarkers (cytokines) and
oxidation/antioxidant index, which were measured and
recorded on days 1 and 10.
Symptom scores
A symptom score sheet was designed based on the typ-
ical format of a 4-point Likert scale [16] with questions
pertaining to four AECOPD symptoms in terms of TCM
syndrome of phlegm-heat obstructing the lung (cough,
phlegm, wheezing, chest congestion) [17]. Members of
the research team administered the questionnaire to
participants. Severity of symptoms was assigned the fol-
lowing points: 0 (none), 2 (mild), 4 (moderate), and 6
(severe). Total score range was from 0 (asymptomatic)
to 30 (severe).
Lung function
Lung function was evaluated in participants using spir-
ometry. Forced expiratory volume in one second (FEV1),
forced vital capacity (FVC) and FEV1 percentage of the
predicted value (FEV1% pred) were tested.Arterial blood gas analysis
Arterial blood gas parameters that were measured were
pH, arterial partial pressure of oxygen (PaO2), arterial
partial carbon dioxide pressure (PaCO2).
Pro-inflammatory biomarkers (cytokines)
Levels of tumor necrosis factor alpha (TNF-α), interleukin-
4 (IL-4), interleukin-8 (IL-8), interleukin-1 beta (IL-1β),
interleukin-6 (IL-6), interleukin-2 (IL-2) in serum were
quantified using an enzyme-linked immunosorbent assay
(ELISA) kit (BD Biosciences, San Diego, CA).
Oxidant/antioxidant balance
Levels of superoxide dismutase (SOD) and malondialde-
hyde (MDA) in serum were quantified using commercially
available kits (Nanjing Jiancheng BioEngineering Institute,
Nanjing, China).
Safety variables
Complete blood count, urine, liver and kidney function
tests, and electrocardiography were performed pre- and
post-treatment (days 1 and 10). Any adverse events that
occurred during the treatment period were recorded.
Adherence
Treatment adherence was assessed by investigators at each
center counting used and unused granule packages.
Study design
This was a multicenter, randomized, double-blind, placebo-
controlled, parallel group clinical trial.
Sample size
As an exploratory study, reference power calculations
were lacking as there have been only a few small-size trials
in China of Xuan Bai Cheng Qi formula for treatment of
AECOPD. Therefore, we inferred data from literature on
TCM therapies with similar efficacy as Xuan Bai Cheng Qi
that treated the same syndrome of phlegm-heat obstruct-
ing the lungs.
The approximate calculation of sample size was de-
termined based on the effective rate of symptom scores
(= (total scores of baseline − total scores of end)/total
scores of baseline × 100%) [18]. The effective rate of
conventional medicine plus placebo (75%) and the ef-
fective rate of conventional medicine plus Xuan Bai
Cheng Qi (90%) were based on comparable studies [19,20].
The control group and trial group adopted 1:1 parallel
design. With 5% one-sided significance level and 90%
statistical power, it was determined that 122 partici-
pants should be randomly assigned to each group, con-
sidering an approximate 10% drop-out rate.
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Participants were randomly allocated to receive Xuan
Bai Cheng Qi formula or placebo. Randomization was
achieved using SAS 8.0 software to generate random
numbers. Simple randomization was used, with each block
comprised of eight participants. Randomization numbers
were assigned to participants in chronological order after
their screening assessments. Participants in the active arm
received Xuan Bai Cheng Qi formula (granules) plus con-
ventional therapy. Participants in the inactive arm received
conventional therapy plus matching placebo.
To ensure allocation concealment, opaque and sealed
emergency letters were printed according to random-
ized list. In the event of an emergency, the participant’sAssessed 
(n =
Completed study (n = 121)
Full analysis set (n = 122)
Per-protocol analysis set (n = 111)
Nonadherent (n = 8)
Used non-study medicine (n = 2)
Withdrew without explanation (n = 1)
Assigned to receive intervention (n = 122)




Figure 1 Trial profile.randomization code and group allocation could be
identified by the emergency envelope, which were on file
at all centers. Third-party investigators were assigned in
each research center as the contact person who preserved
and recorded the randomization information. They did
not have contact with other trial investigators, therefore,
they did not affect enrollment or randomization.
Xuan Bai Cheng Qi and placebo granules were re-
packaged in identical wrappers at each center before dis-
tribution to participants, and numbered sequentially ac-
cording to randomization schedule. Outcome assessments
were made by an independent statistician who was blinded
to group allocation, intervention, and trial management
and did not take part in any other part of the trial. BothExcluded (n = 55)
Did not meet inclusion criteria: 28




Completed the study (n = 121)
Full analysis set (n = 122)
Per-protocol analysis set (n = 118)
Nonadherent (n = 3)
Withdrew without explanation (n = 1)
Assigned to the control (n = 122)
Placebo and conventional treatment
ed (n = 244)
nters)
Table 3 Baseline characteristics of participants
XBCQ (n = 122) Control (n = 122)
Age (SD), y 70.1 ± 9.8 70.7 ± 9.8
Body mass index (SD), kg/m2 23.36 ± 3.44 22.76 ± 3.11
Gender (male/female)
Male (n) % 88 (72.1%) 82 (67.2%)
Female (n) % 34 (27.9%) 40 (32.8%)
Body temperature (°C) 36.68 ± 0.56 36.66 ± 0.58
Exacerbation
Frequency (times) 2.8 ± 1.28 2.6 ± 1.24
Currently exacerbation 3.5 ± 1.36 3.5 ± 1.29
Smoking status
Currently smoking, n (%) 22 (18.03%) 16 (13.11%)
Never smoked, n (%) 54 (44.26%) 52 (42.62%)
Ever smoked, n (%) 46 (37.70%) 54 (44.26%)
No. of packs/year 299.8 ± 170.0 337.9 ± 192.6
FEV1/FVC 55.02 ± 10.477 56.91 ± 9.592
GOLD classification
GOLD stage I, n (%) 10 (8.20%) 9 (7.38%)
GOLD stage II, n (%) 56 (45.90%) 58 (47.54%)
GOLD stage III, n (%) 47 (38.52%) 45 (36.89%)
GOLD stage IV, n (%) 9 (7.38%) 10 (8.20%)
Abbreviations: COPD chronic obstructive pulmonary disease, FEV1 forced
expiratory volume in one second, FVC forced vital capacity, GOLD Global
Initiative for Chronic Obstructive Lung Disease, SD standard deviation,
XBCQ Xuan Bai Cheng Qi.
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of study.
Statistical analysis
All data were entered with Epidata 3.0 software (The
EpiData Association, Odense, Denmark) by two independ-
ent data recorders. All randomized patients were included
in data analysis. Full analysis set (FAS) was used to analyze
the baseline data and outcome data of the cases that went
through randomization and received treatment. Each par-
ticipant underwent at least one time-point observation
during the trial. Partially missing data were imputed with
the use of the last-observation-carried-forward (LOCF)
method, whereby missing values were replaced by the last
non-missing value. Per-protocol analysis set (PPS) was
used to analyze the evaluation data of cases that com-
pleted the trial without major protocol deviations.
Continuous variables were analyzed using repeated-
measures analysis of variance (ANOVA) and/or analysis of
covariance. Mauchly’s test was used to assess sphericity in
the repeated measures ANOVAs, and the Greenhouse
Geisser correction was applied to the degrees of freedom
(DFs) if necessary. Main effects for time, for the inter-
action between time and the intervention group, and for
the overall difference between groups (Xuan Bai Cheng Qi
versus placebo) were assessed. Categorical variables were
analyzed using chi-square test, Fisher’s exact test, or
Cochran-Mantel-Haenszel test. The effect size estimate
and 95% confidence interval (CI) were applied for compar-
ing the treatments. All statistical procedures were per-
formed with SPSS 17.0 software (SPSS Inc, Chicago, IL).
Data monitoring committee
A data monitoring committee at Dongzhimen Hospital
comprised of clinicians, statisticians, epidemiologists over-
saw data analyses and ensured protocol adherence and




A total of 299 COPD patients were assessed for eligibility
in the trial. After 55 patients were excluded due to not
meeting eligibility criteria, 244 patients were enrolled
and underwent randomization (Figure 1). Two partici-
pants dropped out on day 7 without explanation, but
they received treatment and also completed one time
point observation. Thus, a total of 242 evaluable partici-
pants were in the study, with 121 in the Xuan Bai Cheng
Qi group and 121 in the control group. The FAS popula-
tion was 244, with 122 in the trial group and 122 in the
control group. Eleven participants were protocol noncom-
pliant, and two participants used non-study medica-
tions, which affected outcome calculation. Ultimately,PPS population was 229, with 111 in the trial group
and 118 in the control group.
In terms of demographic and baseline characteristics
of participants (Table 3), there were no significant differ-
ences between the Xuan Bai Cheng Qi and control groups
in gender, age, course of disease, body mass index (BMI),
exacerbations, FEV1/FVC, and GOLD classification of
lung function.
Symptom scores
ANOVA revealed a significant main effect of group
(P = .001), a significant main effect of time (P < .001), as
well as a significant group × time interaction (P < .001).
Total symptom scores of the Xuan Bai Cheng Qi group
were significantly lower over time compared with those
of the control group (FAS: mean difference −1.84, 95%
CI −2.66 to −1.03, P < .001; PPS: mean difference −1.87,
95% CI −2.71 to −1.03, P < .001). This difference was
achieved within the first 3 days of treatment (FAS: mean
difference −2.57, 95% CI −3.64 to −1.49, P < .001; PPS:
mean difference −2.60, 95% CI −3.70 to −1.49, P < .001).
At days 3, 5, 7, and 10, there were significant differences
in total symptom scores of the Xuan Bai Cheng Qi group
compared with those of the control group (Table 4).
Table 4 Total symptom scores in Xuan Bai Cheng Qi and control groups during 10 − day treatment
Total symptom scores Full analysis set Per − protocol analysis set
XBCQa Controla Treatment effectb XBCQa Controla Treatment effectb
(n = 122) (n = 122) (95% CI; P-value) (n = 122) (n = 122) (95% CI; P-value)
1 d 19.70 (4.23) 20.10 (4.28) −0.39 (−1.47, 0.68; .471) 19.64 (4.24) 20.09 (4.32) −0.45 (−1.56, 0.67; .433)
3 d 13.92 (4,46) 16.48 (4.08) −2.57 (−3.64, −1.49; < .001) 13.82 (4.50) 16.42 (3.95) −2.60 (−3.70, −1.49; < .001)
5 d 10.64 (4.28) 13.20 (4.18) −2.56 (−3.63, −1.49; < .001) 10.59 (4.24) 13.12 (4.10) −2.52 (−3.61, −1.44; < .001)
7 d 7.72 (4.34) 9.64 (3.68) −1.92 (−2.93, −0.90; < .001) 7.64 (4.38) 9.54 (3.65) −1.90 (−2.95, −0.86; < .001)
10 d 5.21 (4.43) 7.00 (3.72) −1.79 (−2.82, −0.76; 0.001) 5.03 (4.29) 6.92 (3.74) −1.89 (−2.93, −0.84; < .001)
Meanc 11.44 (3.36) 13.28 (3.09) −1.84 (−2.66, −1.03; < .001) 11.34 (3.40) 13.22 (3.05) −1.87 (−2.71, −1.03; < .001)
Abbreviations: CI confidence interval, XBCQ Xuan Bai Cheng Qi.
Mauchly’s test of sphericity was applied: W = .506, P < .001.
aData presented as mean (SD).
bRepeated-measures analysis of variance (ANOVA) for estimate with 95% confidence interval for difference.
cMean = change from baseline.
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FEV1, FVC, and FEV1 % pred were significantly higher
over time in the Xuan Bai Cheng Qi group compared
with the same parameters in the control group (FEV1,
FAS: mean difference 0.14, 95% CI 0.06 to 0.22, P < .001,
PPS: mean difference 0.13, 95% CI 0.06 to 0.21, P = .001;
FVC, FAS: mean difference 0.17, 95% CI 0.06 to 0.28,
P = .002, PPS: mean difference 0.16, 95% CI 0.05 to
0.27, P = .004; FEV1 % pred, FAS: mean difference 7.33,
95% CI 4.58 to 10.07, P < .001, PPS: mean difference
7.20, 95% CI 4.37 to 10.03, P < .001) (Table 5).
Arterial blood gas analysis
At day 10, PaO2 and PaCO2 were significantly improved
in the Xuan Bai Cheng Qi group compared with PaO2











FAS (122,122) 1.18 (0.41) 1.44 (0.49) 0.24 (0.29) 1
PPS (111,118) 1.20 (0.42) 1.44 (0.49) 0.24 (0.29) 1
FVC (liters)
FAS (122,122) 2.16 (0.62) 2.40 (0.67) 0.23 (0.38) 2
PPS (111,118) 2.17 (0.60) 2.40 (0.65) 0.23 (0.38) 2
FEV1 % pred
FAS (122,122) 51.54 (19.49) 62.39 (19.57) 10.59 (11.76) 52
PPS (111,118) 52.60 (19.74) 63.38 (19.36) 10.49 (11.84) 52
Abbreviations: CI confidence interval, COPD chronic obstructive pulmonary disease, F
predicted value, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstruc
aFAS population was 122 in the XBCQ group and 122 in the control group; PPS pop
bData presented as mean (SD).
cP < .01: Change between pre-treatment and post-treatment (within group differenc
dCovariance analysis estimate with 95% confidence interval for difference.difference 4.75, 95% CI 1.21 to 8.28, P = .009, PPS: mean
difference 4.08, 95% IC 0.04 to 7.76, P = .030; PaCO2,
FAS: mean difference −2.48, 95% CI −4.53 to −0.44,
P = .018, PPS: mean difference −2.69, 95% CI −4.56
to −0.81, P = .005). There was no significant difference
between the Xuan Bai Cheng Qi and control groups in
PH (FAS: mean difference −0.00, 95% CI −0.01 to 0.01,
P = .894, PPS: mean difference −0.00, 95% CI −0.01 to
0.01, P = .794) (Table 6).
Pro-inflammatory biomarkers (cytokines)
Only 22 participants in the Xuan Bai Cheng Qi group
and 16 participants in the control group permitted their
blood to be collected at the end of the trial on day 10.
Therefore, comparison of biomarker levels between the
two groups was based on these numbers of participants.nd control groups before and after 10-day treatment
Controlb Treatment effectd






.19 (0.40) 1.29 (0.47) 0.10 (0.31) 0.14 (0.06, 0.22; < .001)
.19 (0.39) 1.29 (0.47) 0.10 (0.31) 0.13 (0.06, 0.21; .001)
.10 (0.58) 2.17 (0.62) 0.08 (0.48) 0.17 (0.06, 0.28; .002)
.11 (0.57) 2.19 (0.60) 0.08 (0.48) 0.16 (0.05, 0.27; .004)
.13 (19.17) 55.35 (20.59) 3.22 (10.53) 7.33 (4.58, 10.07; < .001)
.17 (19.27) 55.56 (22.68) 3.39 (10.50) 7.20 (4.37,10.03; < .001)
EV1 forced expiratory volume in one second, FEV1 % pred FEV1 percentage of
tive Lung Disease, Mean Dmean difference, XBCQ Xuan Bai Cheng Qi.
ulation was 111 in the XBCQ group and 118 in the control group.
e by paired t-test).
Table 6 Arterial blood gas analysis in Xuan Bai Cheng Qi and control groups before and after 10-day treatment






Mean D Day 1
(Baseline)
Day 10 (End) Mean D
PH
FAS (122,122) 7.41 (0.05) 7.41 (0.04) 0.01 (0.05) 7.42 (0.05) 7.42 (0.05) −0.00 (0.05) −0.00 (−0.01, 0.01; .894)
PPS (111,118) 7.41 (0.05) 7.41 (0.04) 0.00 (0.05) 7.42 (0.05) 7.42 (0.05) −0.00 (0.05) −0.00 (−0.01, 0.01; .794)
PaO2
FAS (122,122) 75.56 (19.38) 85.69 (16.42) 13.13 (18.12)c 71.47 (18.90) 80.49 (15.91) 9.01 (17.49)c 4.75 (1.21, 8.28; .009)
PPS (111,118) 71.91 (19.28) 85.11 (16.59) 13.20 (18.50)c 71.27 (19.08) 80.76 (15.96) 9.49 (17.31)c 4.08 (0.04, 7.76; .030)
PaCO2
FAS (122,122) 47.41 (10.04) 39.52 (11.55) −7.89 (12.27)c 39.52 (11.55) 41.45 (8.33) −4.76 (8.97)c −2.48 (−4.53, −0.44; .018)
PPS (111,118) 46.46 (13.32) 38.93 (9.47) −7.53 (11.49)c 45.90 (11.82) 41.38 (8.41) −4.52 (8.83)c −2.69 (−4.56, −0.81; .005)
Abbreviations: CI confidence interval, Mean Dmean difference, PaO2 arterial partial pressure of oxygen, PaCO2 arterial partial carbon dioxide pressure,
XBCQ Xuan Bai Cheng Qi.
aFAS population was 122 in the XBCQ group and 122 in the control group; PPS population was 111 in the XBCQ group and 118 in the control group.
bData presented as mean (SD).
cP < .01: Change between pre − treatment and post − treatment (within group difference by paired t − test).
dCovariance analysis estimate with 95% confidence interval for difference.
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were significantly decreased in the Xuan Bai Cheng Qi
group compared with levels in the control group
(Table 7).
Oxidant/antioxidant balance
Based on serum collected from the 20 participants in
the Xuan Bai Cheng Qi group and 20 participants in the
control group, MDA level was significantly decreased in
the Xuan Bai Cheng Qi group compared with that in
the control group (mean difference −1.07, 95% CI −1.55
to −0.59, P < .001), while SOD level in the Xuan Bai
Cheng Qi group was significantly higher than that in
the control group (mean difference 6.09, 95% CI 2.94 to
9.23, P < .001) (Table 8).Table 7 Pro-inflammatory biomarker changes in Xuan Bai Che
treatment







TNF − α (pg/mL) 20.34 (4.90) 4.92 (1.90) −15.42 (4.88) 18.90 (
IL − 2 (pg/mL) 129.72 (18.27) 53.50 (18.21) −76.23 (25.21) 129.54 (
IL − 4 (pg/mL) 5.98 (1.49) 2.36 (0.56) −3.61 (1.78) 6.15 (1
IL − 6 (pg/mL) 3.95 (0.80) 2.06 (0.53) −1.89 (0.95) 3.81 (0
IL − 8 (pg/mL) 18.33 (3.93) 9.09 (3.54) −9.24 (6.11) 18.01 (
IL − 1β (pg/mL) 13.42 (2.12) 8.36 (1.02) −7.89 (12.27) 12.86 (
Abbreviations: CI confidence interval, IL − 1β interleukin − 1 beta, IL − 2 interleukin − 2
difference, TNF − α tumor necrosis factor alpha, XBCQ Xuan Bai Cheng Qi.
aData presented as mean (SD).
bP < .05.
cP < .01: change between pre − treatment and post − treatment (within group differ
dCovariance analysis estimate with 95% confidence interval for difference.Safety variables
Adverse events were recorded during the study period.
Mild diarrhea occurred in six participants (4.92%) in the
Xuan Bai Cheng Qi group and in two participants (1.64%)
in the control group, but these incidents were not statis-
tically significant (P = .281). There were no significant
differences in blood, urine, and liver and kidney func-
tion tests, or in electrocardiography results before and
after the study period between the Xuan Bai Cheng Qi
and control groups (Table 9).
Adherence
Adherence based on empty granule package count was
high and similar in both the Xuan Bai Cheng Qi and
control groups.ng Qi and control groups before and after 10 − day







3.61) 6.47 (1.56) −12.43 (3.28)c −1.70 (−2.86, −0.54; .005)
28.70) 84.10 (11.01) −45.43 (32.88)c −30.60 (−40.94, −20.25; < .001)
.36) 3.38 (1.25) −2.77 (1.70)c −1.02 (−1.65, −0.39; .002)
.94) 2.76 (0.67) −1.06 (0.48)c −0.74 (−1.20, −0.39; < .001)
4.17) 14.92 (3.86) −3.08 (5.36)b −5.80 (−8.26, −3.34; < .001)
1.98) 9.23 (1.54) −4.76 (8.97)c −0.94 (−1.78, −0.10; .029)
, IL − 4 interleukin − 4, IL − 6 interleukin − 6, IL − 8 interleukin − 8, Mean Dmean
ence by paired t − test).
Table 8 Serum SOD and MDA in Xuan Bai Cheng Qi and control groups before and and after treatment
Variables XBCQa (n = 20) Controla (n = 20) Treatment effectc
(95% CI; P value)
Day 1 (Baseline) Day 10
(End)





SOD (U/mL) 20.56 (4.95) 28.54 (4.66) 7.98 (5.97) 21.90 (5.32) 23.24 (6.76) 1.33 (4.21) 6.09 (2.94, 9.23; < .001)
MDA (nmol/mL) 4.43 (1.52) 1.89 (0.52) −2.54 (1.65) 4.52 (1.44) 2.98 (1.45) −1.54 (0.94)b −1.07 (−1.55, −0.59; < .001)
Abbreviations: CI confidence interval, MDAmalondialdehyde, Mean Dmean difference, SOD superoxide dismutase, XBCQ Xuan Bai Cheng Qi.
aData presented as mean (SD).
bP < .01: Change between pre-treatment and post-treatment (within group difference by paired t-test).
cCovariance analysis estimate with 95% confidence interval for difference.
Liu et al. BMC Complementary and Alternative Medicine 2014, 14:239 Page 9 of 11
http://www.biomedcentral.com/1472-6882/14/239Discussion
This multicenter, randomized, double-blind, placebo-
controlled study showed that as an adjuvant treatment
Xuan Bai Cheng Qi formula produced a significant
improvement in symptoms associated with AECOPD
of the TCM syndrome type, phlegm-heat obstructing
the lungs. Total symptom scores from baseline showed
that Xuan Bai Cheng Qi ameliorated cough, phlegm,
wheezing, and chest congestion. Lung function and
blood gas levels were also significantly improved in
the intervention group compared with the control
group.
AECOPD appears to be triggered by increased airway
inflammation. A number of pro-inflammatory cytokines,
such as TNF-α, IL-4, IL-8, IL-1β, IL-6, IL-2, have been
detected during COPD exacerbation and have been re-
ported to be increased in both sputum and serum during
COPD exacerbations [21-25]. In our study, levels of
pro-inflammatory mediators in the Xuan Bai Cheng Qi
group were lower than those in the control group. We
propose that as an adjuvant treatment, Xuan Bai Cheng
Qi contributed to regulating systemic inflammatoryTable 9 Safety profile





WBC (109/L) 8.33 (3.49) 7.51 (2.81)
HB (g/L) 138.2 (24.0) 138.6 (31.0)
RBC (1012/L) 4.39 (0.65) 4.38 (0.64)
PLT (109/L) 198.4 (62.4) 210.4 (78.7)
NEUT (%) 69.6 (14.4) 64.7 (12.9)
ALT (U/L) 21.0 (11.1) 22.2 (12.1)
BUN (mmol/L) 5.6 (1.6) 5.7 (2.4)
CR ( μmmol/L) 75.4 (20.4) 74.0 (21.5)
BUN (n)c 27 (122) 32 (122)
ECG (n)c 56 (122) 45 (122)
Abbreviations: ALT alanine aminotransferase, BUN blood urea nitrogen, Cr creatinine,
PLT platelets, RBC red blood cell, WBCwhite blood cell.
aCovariance analysis for between group after treatment.
bData presented as mean (SD).
cChi-square test for between group after treatment.response. Previous studies have shown that the active
ingredients in the herbs that comprise Xuan Bai Cheng
Qi formula, such as emodin in Rheum officinale Baill
[26], calcium sulfate in Gypsum fibrosum [27], triter-
penoid saponins in Trichosanthes kirilowii Maxim [28],
and amygdalin in Semen Armeniacae amarum [29]
possess anti-inflammatory effects.
Oxidative stress is another component in the patho-
genesis of AECOPD [30-32]. Oxidative stress can in-
duce extensive tissue damage and activate the nuclear
factor kappa-light-chain-enhancer of activated B cells
(NF-κB) pathway, which provokes the release of pro-
inflammatory molecules, such as TNF-α, IL-8. Our results
indicate that compared with the control group, SOD activ-
ity was higher and MDA content was lower in the Xuan
Bai Cheng Qi group. Thus Xuan Bai Cheng Qi may con-
tribute to restoring oxidant/antioxidant balance.
Mention needs to be made that of the 122 participants
each in the Xuan Bai Chang Qi and control groups, only
20 and 16 participants, respectively, allowed their serum
to be collected at the end of the trial for evaluation of





9.38 (7.95) 7.53 (3.11) .843
136.3 (28.1) 134.3 (28.1) .310
4.33 (0.61) 4.27 (0.57) .263
209.4 (76.9) 207.5 (68.4) .178
68.9 (14.9) 62.1 (13.4) .111
21.9 (16.3) 22.5 (14.1) .920
6.1 (2.8) 5.8 (2.8) .511
85.2 (46.5) 80.3 (35.9) .863
15 (122) 7 (122) .116
57 (122) 47 (122) .895
ECG electrocardiogram, HB hemoglobin, NEUT neutrophilic granulocyte,
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ticipants in each group permitting serum collection. For
ethical considerations, we respected participants’ inclin-
ation. Nevertheless, based on the results we did obtain,
there were significant differences between the two groups
as described above.
Xuan Bai Cheng Qi formula appears to be safe. Serious
untoward effects were not reported during the study. Six
participants in the Xuan Bai Cheng Qi group experi-
enced mild diarrhea. Toxicological studies on the active
ingredient in individual medicinals in Xuan Bai Cheng
Qi formula have shown that long-term use of Rheum
officinale Baill may induce liver degeneration [33]; tox-
icity of Semen Armeniacae amarum is mainly from
amygdaloside, which can produce the toxic hydrocyanic
acid by enzymatic hydrolysis [34]; Trichosanthes kirilowii
Maxim is not known to be toxic [35]; and Gypsum fibro-
sum is mildly toxic [36]. Typically, during processing of
raw medicinals and decoction of the combined medici-
nals, it is likely that the individual toxic effects are re-
duced or even neutralized [37].
The main limitation of this study is its short duration
of 10 days. Changes in frequency of acute exacerbations
of COPD were not observable. In addition, the compari-
son between biomarkers and levels of SOD and MDA
are of an observational nature, which may therefore be
biased. Further studies should be performed to evaluate
the long-term efficacy of Xuan Bai Cheng Qi formula as
an adjuvant treatment for AECOPD.Conclusions
Traditional Chinese medicinals are commonly used to
treat lung conditions, including acute exacerbation of
chronic obstructive pulmonary disease (AECOPD). How-
ever, there is a lack of modern research to validate such
empirical remedies. To the best of our knowledge, this
study is the first large-scale, multicenter randomized con-
trol trial evaluating the efficacy and safety in humans of
the traditional formula Xuan Bai Cheng Qi as an adjuvant
treatment for AECOPD of the TCM syndrome type,
phlegm-heat blocking the lungs. Our results found that
compared with placebo, Xuan Bai Cheng Qi appears to be
safe and effective for AECOPD with improvement in
symptoms as well as biomarker parameters.Abbreviations
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